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40-word summary of the article’s main point 
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cutaneous T-cell lymphoma patients, compared to organ transplant recipients and healthy 
adults. This suggests that dermal CuV DNA is significantly associated with CTCL. 
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Abstract 
Background. Three new parvoviruses of Protoparvovirus genus, bufavirus (BuV), tusavirus 
(TuV) and cutavirus (CuV), have recently been discovered in diarrheal stools. CuV was further 
detected in a proportion of cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) skin 
samples and in one melanoma.  
Patients and methods. With novel multiplex quantitative PCR (qPCR) and antibody assays, we 
studied three patient groups for BuV, TuV and CuV DNA and IgG: CTCL patients, 
immunosuppressed solid-organ transplant recipients, and immunocompetent healthy adults.   
Results. CuV DNA was detected in skin biopsies of 4/25 (16.0%) CTCL and 4/136 (2.9%) 
transplant patients, but not in any of 159 skin samples of 98 healthy adults. The dermal CuV-
DNA prevalence was significantly higher in CTCL patients than in the other subjects. CuV DNA 
was further detected in healthy skin of four organ transplant recipients, two of whom also 
had CuV-positive skin carcinomas. One CTCL patient harbored CuV DNA in both malignant 
(CTCL, melanoma) and non-malignant skin and sentinel lymph nodes, but not in his prostate. 
The CuV IgG seroprevalences were among CTCL patients 9.5% (4/42), transplant recipients 
6.5% (8/124), and healthy adults 3.8% (3/78). BuV and TuV DNAs were absent and antibodies 
infrequent in all cohorts. Parvoviral antibodies were shown to persist for ≥20 years and 
dermal CuV DNA for four years. All three CuV-DNA-positive patients, with both biopsies and 
sera available, were CuV-IgG positive.  
Conclusion. Our results suggest that dermal CuV DNA carriage is associated with CTCL. Any 
putative roles of CuV in the carcinogenesis must be determined in forthcoming studies. 
 
Introduction 
Cutavirus (CuV) is the newest human parvovirus described [1]. It belongs to the 
Protoparvovirus genus together with two other newly discovered parvoviruses, bufavirus 
(BuV) and tusavirus (TuV), identified in 2012 and 2014 [2-4]. These three protoparvoviruses 
were all originally discovered in diarrheal feces, and CuV DNA was additionally identified by 
in silico analysis in pre-existing metagenomic libraries of skin biopsies from two cutaneous T-
cell lymphoma (CTCL) patients. PCR studies further showed CuV DNA in the malignant lesions 
of 2/15 French CTCL patients, while 26 other skin manifestations and 3 healthy skin samples 
were CuV-DNA negative [1]. CTCL represents a group of malignancies of mature T cells, for 
which viral etiology has been long sought but not found [5]. CuV DNA was recently detected 
also in the cutaneous melanoma of a patient in Denmark [6]. Like other human parvoviruses, 
CuV induces a humoral immune response; however, with low seroprevalences (0-5.6%) in all 
countries analyzed [7]. Further studies of CuV-DNA occurrence in skin and other tissues as 
well as serological studies are needed to fully uncover the etiological role of this emerging 
virus in neoplastic and other human diseases.   
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In this study, we set up a multiplex quantitative PCR (qPCR) to detect and quantify BuV, TuV 
and CuV DNAs in altogether 355 healthy and diseased human skin from 25 CTCL patients, 136 
organ-transplant recipients, and 98 healthy adults. Furthermore, we analysed 266 serum 
samples from 244 subjects with in-house BuV1-3-, TuV-, and CuV-specific IgG EIAs to assess 
the human protoparvovirus seroprevalences in these cohorts.  
 
Materials and methods 
 
Patients and Samples 
 
Patients with cutaneous T-cell lymphoma 
The CTCL patients were diagnosed, based on detailed dermatopathological and 
immunohistological examination, at the Department of Dermatology, Helsinki University 
Hospital [8]. Formalin-fixed and paraffin-embedded (FFPE) skin biopsies were studied of CTCL 
lesions from 25 CTCL patients, 23 with mycosis fungoides and two with leukemic Sezary 
syndrome (median age 64 years, range 32 – 89 years). From two patients with CuV DNA in the 
original skin biopsy, additional tissue biopsies were retrieved from the pathology archives. 
Serum samples were available of a cohort of 42 CTCL patients [9], including 2 of the CTCL 
patients whose skin biopsies were analyzed.  
 
Transplant recipients  
The immunosuppressed solid-organ transplant cohort consisted of 136 patients (median age 
62 years, range 22 – 83 years, data not available from 5 patients): 131 liver-, four kidney-, and 
one heart-transplant recipients. The patients had received the organ transplant more than 
five years ago (median 10 years, range 5-26 years) and they all received calcineurin inhibitors 
with declining levels, but remained moderately immunosuppressed throughout the follow-up.  
 
Fresh skin biopsies were taken as 5-mm punch biopsies and rapidly frozen and stored at -70°C 
until analysis. Healthy skin samples were available from 133 patients, in nearly all cases from 
the clavicular region. Biopsies from suspected malignant or premalignant (19 carcinoma, 1 
melanoma, 4 actinic keratosis) skin were available from 19 patients (1-4 biopsies per patient). 
Altogether, DNA of 163 skin biopsies were extracted and analyzed. A corresponding serum 
sample, taken the same day as the skin biopsy, was available from 123 patients. Additionally, 
of the CuV, BuV or TuV sero- or genopositive patients, 1-3 serum samples of each patient 
were obtained at various time points before the skin biopsy. In total, 146 serum samples were 
available from 124 patients.  
 
Immunocompetent healthy adults  
Healthy adults (total n=98) with 159 skin biopsies obtained from areas of epicutaneous tests 
with allergens (n=74) or irritants (n=85) were included as a control group (median age 43 
years, range 18–67 years). Two adults had mild psoriasis and 13 had atopic dermatitis, but 
none had known skin malignancies. Four-mm punch biopsies of skin were obtained from the 
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backs of all subjects and were then immersed in RNA-later liquid, frozen and stored at -80°C. 
A corresponding serum sample was available from 78 patients.  
 
Ethics 
A written informed consent was obtained from the subjects, and the Ethics Committee of 
Helsinki and Uusimaa Hospital District or the National Supervisory Authority for Welfare and 
Health (Valvira) approved the study. The study was conducted in accordance with the relevant 
guidelines and regulations. 
 
DNA extraction 
 
DNA from FFPE skin samples (1-20 x 10µm sections, depending on the amount of tissue in the 
blocks) was extracted with QIAamp DNA FFPE Tissue Kit (Qiagen) with some modifications to 
the manufacturer’s instruction (see Supplementary information). DNA from freshly frozen 
skin biopsies (~ 4 to 5 mm diameter) was extracted with the QIAamp DNA Mini Kit or AllPrep 
DNA/RNA/miRNA Universal Kit (Qiagen) and from sera (200 µl) with QIAamp DNA Blood Mini 
Kit (Qiagen), according to the manufacturer’s instructions. The extracted DNA was eluted in 
100 µl AE buffer. All DNA extracts were stored at -20°C. 
 
BuV-TuV-CuV multiplex qPCR 
 
To detect and quantify BuV, TuV, and CuV DNA, a multiplex real-time quantitative PCR was 
developed with primers and hydrolysis probes located in the NS1 region of BuV [10] and the 
VP2 regions of TuV and CuV (Supplement and Table S1).  
 
After optimization, the PCR reactions consisted of 1x Maxima probe qPCR Master Mix 
(Thermo Scientific) without ROX as passive reference dye, 0.5 µM concentration of each 
primer (except for the CuV fwd primer which was 1.0 µM), 0.2 µM each of BuV and TuV 
probes, 0.4 µM of CuV probe, 5µL template, and molecular biology-grade H2O to a final 
volume of 25 µL. After initial denaturation and enzyme activation at 95°C for 10 min, 45 cycles 
of amplification consisting of 15s at 95°C and 1 min at 62°C were performed. 
 
All qPCR determinations were done in duplicates with the AriaMx Realtime PCR System 
(Agilent Technologies) and all positive samples were confirmed by singleplex qPCR, cloned 
and sequenced. The CuV DNA-positive samples were further re-amplified to obtain longer 
583nt- or 230nt-PCR amplicons by using the primers CuV 580 fwd or CuV 230 fwd and CuV 
rev (Table S1). To avoid contamination, the FFPE-blocks were cut with disposable blades, the 
samples, master mix components, and plasmid templates were handled in separate rooms 
and all templates were added in laminar hoods. All runs included molecular biology-grade 
water as no-template controls and plasmids as positive controls and for generation of 
standard curves (see Supplementary Material).  
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All DNA extracts from clinical samples were subjected to the reference gene, RNase P, qPCR 
for quality control and cell-count quantification, as described [11]. Parvoviral quantity is 
expressed as copies per 106 cells.  
 
BuV1-3-TuV-CuV IgG EIA  
 
A total of 266 serum samples from 42 CTCL and 124 transplant patients as well as 78 
immunocompetent adults were analysed by an in-house BuV1-3-TuV-CuV IgG EIA and all 
samples showing an OD >0.1 were confirmed with competition EIA to block cross-reactive 
antibody binding, as described [7, 12] and outlined in the Supplement.  
 
Statistical analysis 
 
Statistics were calculated with R, version 3.4.3 (R Development Core Team, Vienna, Austria) 
for Mann-Whitney U, Pearson’s c2, and one-way ANOVA tests.  
 
Results 
 
Multiplex qPCR from tissue biopsies 
CuV DNA was detected in the cutaneous lymphoma lesions of 4/25 (16.0%) CTCL patients 
(Table 1). The patient with the highest CuV DNA quantity (C-53; up to 7x108 copies per one 
million cells) had also melanoma and prostate cancer (Table 2). We thus studied 12 additional 
FFPE tissue samples from this patient and found that two sentinel lymph nodes and both non-
malignant and malignant (melanoma) skin samples were CuV-DNA positive with variable viral 
loads. Interestingly, the highest CuV loads were observed in the CTCL and pre-cancerous CTCL 
skin biopsies, whereas the two prostate cancer samples of this patient and those of patient 
C-15, were all CuV DNA negative. No BuV or TuV DNAs were found in any of the FFPE tissue 
biopsies of the 25 CTCL patients.  
 
Of the 136 organ transplant recipients, 4 (2.9%) harbored CuV DNA in skin (Table 1), but the 
corresponding serum samples were CuV-DNA negative. Two of these 4 patients had also skin 
cancer (Table 2); one was CuV-DNA positive in both healthy skin and basal cell carcinoma 
(patient P-065), and the other in healthy skin, pre-malignant skin and squamous cell 
carcinoma (patient P-A). The two remaining CuV DNA-positive biopsies were of healthy skin 
(P-022 and P-108, Table 2). No BuV or TuV DNAs were found in any of the 163 skin biopsies 
from the 136 transplant patients.   
 
All 159 freshly frozen skin samples from the 98 immunocompetent adults were negative for 
BuV, TuV and CuV DNA (Table 1). Overall, the CuV DNA prevalence in skin was significantly 
higher in CTCL patients than in either the transplant recipients or healthy controls (P <.001; 
Pearson’s c2 test). In the three patients with samples available from both malignant and non-
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malignant skin (Table 2), the CuV-DNA loads were higher in the malignant skin samples, but 
the sparse number of samples did not allow valid statistical analysis. The housekeeping-gene 
qPCR was positive in all samples.  
 
Sequencing of the CuV DNA 
All CuV-qPCR products were cloned and confirmed by sequencing to be identical or nearly 
identical to those in GenBank. The longer CuV amplicon of 583 nts was obtained from six skin 
tissues of the four transplant patients and from five CuV high-copy-number tissues of CTCL 
patient C-53 (Table 2). All long CuV sequences amplified from different tissues of the same 
individual were identical, whereas those from distinct patients varied (Figure 1). Furthermore, 
the cloned 91-nt amplicon of patient C-26 had 2-3 mismatches compared to the others. All 
sequences are in GenBank, accession nos. MH822920-30, or in Figure S2. 
 
Protoparvovirus IgG EIAs 
Of the 25 CTCL patients with skin biopsies, corresponding serum samples were available from 
only two, one was CuV-IgG positive and one negative. However, including a cohort of 40 
additional CTCL patient sera, 2/42 (4.8%) harbored BuV1 IgG and 4/42 (9.5%) CuV IgG (Table 
3). None of the 42 patients showed BuV2, BuV3 or TuV IgG. Unfortunately, no corresponding 
serum samples were available from the CTCL patients with CuV DNA-positive skin.  
 
The overall IgG seroprevalence in the organ transplant cohort was 2.4% for all bufaviruses 
(0.8% for each BuV genotype), 0.8% for TuV and 6.5% for CuV (Table 3). The BuV1 IgG-positive 
patient was also CuV-IgG positive, all others were IgG positive for only a single 
protoparvovirus. Further, 1-3 serum samples from all seropositive patients (n=11), obtained 
at different times before the skin biopsy, were analyzed for protoparvovirus IgG (Table 4). 
Nine of 11 patients were seropositive already in the first sample, which was taken in most 
cases before or at the time of transplantation. In addition, these patients showed BuV and/or 
CuV IgG for 5 to >20 years. Besides these nine patients with long-term seropositivity, one 
patient (P-093) seroconverted for CuV and another (P-055) for TuV during the post-transplant 
follow up (Table 4). The TuV IgG remained for 10 years, whereas the transient CuV IgG could 
have passively originated from blood transfusion.  
 
Of the four CuV DNA-positive transplant recipients, serum samples were available from three, 
and all showed CuV IgG with high OD values (Table 4). In contrast, all five CuV IgG-positive 
recipients without detectable CuV DNA in skin showed significantly lower CuV IgG values in 
the corresponding serum sample (P < .05 (Mann-Whitney U test). 
 
None of the healthy adults had BuV1-3 or TuV IgG, whereas CuV IgG at low OD (0.123-0.192, 
verified by blocking) was observed in 3.8% of the 78 serum samples available from this cohort 
(Table 3). 
 
Discussion 
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Thus far, human protoparvovirus DNA has been detected mainly in diarrheal feces and two 
studies have shown the presence of CuV DNA in altogether four malignant CTCL skin lesions 
and in one melanoma [1, 6]. Immunosuppressed organ transplant recipients have in general 
been shown to be at risk for epithelial skin cancers [13]. In this study, we detected by qPCR 
CuV DNA in skin biopsies of 16.0% of CTCL patients versus 2.9% of organ-transplant recipients 
but not in any of 98 healthy adults. Both prevalence differences are highly significant (P < 
.001, Pearson’s c2 test). All samples were BuV and TuV DNA negative. In the original 
publication of CuV discovery, it was detected by PCR in 2/15 CTCL lesions, whereas 10 skin 
carcinomas, 16 other skin diseases (8 parapsoriasis, 4 eczema and 4 eczematoid dermatitis), 
and 3 healthy skin samples were all CuV-DNA negative [1]. Furthermore, one out of 10 
melanoma skin samples was reported to harbor CuV DNA [6]. Interestingly, we discovered 
CuV DNA both in non-malignant and malignant skin of three subjects: two transplant 
recipients had CuV DNA in basal or squamous cell carcinoma tissue and in healthy skin, 
whereas one CTCL/MF patient had CuV in both early- and late-stage CTCL lesions, in 
melanoma, atypical moles, benign skin tumors, and lymph nodes, but not in his prostate 
samples. This triple-cancer patient harbored CuV DNA in his tissues for at least four years 
before CTCL diagnosis. Of the overall 215 patients without skin cancer, only two (0.9%) 
harbored dermal CuV DNA and both were moderately immune suppressed due to 
transplantation; all other patients with dermal CuV DNA had skin cancer. The difference of 
dermal CuV-DNA prevalence between cancerous and non-cancerous patients was highly 
significant [6/44 (14.0%) vs. 2/215 (0.9%), P < .0001, Pearson’s c2-test].  
 
The classical human parvovirus B19 (B19V) has been shown to persist for life in most solid 
tissues including skin of healthy immunocompetent individuals [14-17]. Similarly, many 
animal parvoviruses persist in their host tissues conferring challenges in laboratory and other 
animal facilities [18-21]. It is thereby possible that CuV does the same. For optimal replication 
parvoviruses generally need rapidly dividing host cells such as fetal, intestinal, or bone-
marrow cells. Some protoparvoviruses therefore show a preference for cancer cells, the 
oncolytic characteristic of which is also utilized in cancer therapy [22]. While the host-cell 
tropism of CuV is unknown, the higher prevalence of CuV DNA observed here in cancerous 
compared to healthy skin could reflect either causality or an incidental finding due to e.g. 
CuV-positive cell migration or enhanced ability of CuV to replicate in rapidly dividing cancer 
cells [5, 22].   
 
The fact that the CTCL skin samples, studied as FFPE, showed higher CuV-DNA prevalences 
than the freshly frozen skin samples of the other subjects, points to a genuine difference in 
genoprevalence, since PCR is known to be less sensitive in FFPE samples. That all negative 
controls remained PCR negative as did the BuV and TuV PCRs, further strengthens the 
credibility of our CuV PCR data. Furthermore, the slight sequence differences seen in the 
phylogenetic tree of the longer 583nt-CuV sequences amplified from different individuals, 
also rules against contamination. Identical long CuV sequences were seen only in samples 
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obtained within the same individual in samples taken up to 4 years apart. Furthermore, 
sequence differences were identified also in the cloned short amplicon of a low-load FFPE 
sample. 
 
All 159 non-malignant freshly-frozen skin biopsies of 98 healthy adults were CuV-DNA free. 
However, the age difference between the healthy adults compared to the other cohorts or 
that the skin samples were not exactly matched to the corresponding body region as the 
malignant lesions, could be argued to affect the CuV-DNA prevalence. However, the age 
profiles of the CTCL and transplant patients were the same, substantiating the significant 
difference in occurrence of CuV DNA. Of note, the difference in seroprevalence between the 
CTCL and healthy cohorts did not reach statistical significance. The CuV seroprevalences in 
these three cohorts concur with our previously observed CuV-IgG prevalences among adults 
in Finland and globally (0-5.6%) [7].  
 
Our retrospective serological analysis indicate that the transplant recipients maintained CuV-
, BuV- or TuV-specific IgG for at least 5-22 years despite immunosuppression. The observed 
BuV IgG seroprevalences in CTCL, transplant, and healthy adult cohorts (0-4.8%) are in line 
with our previously published BuV prevalence of 2-3% in Finland [7, 12], but contrasts sharply 
to the 56% - 85% seroprevalences in the Middle East and Africa [7].  In EIA, BuV2 and CuV 
antibodies cross-react, which is logical as the VP2s differ at the amino acid level by only 18%. 
Such CuV-BuV2 cross-reactivity was also observed in our previous study, yet could 
successfully be blocked by competition [7]. Here as before, dual seropositivity for these two 
viruses was infrequent. The clinical performance of our competition assay was further 
augmented by the data from the three patients with both CuV DNA in skin and CuV-specific 
IgG in serum. However, we also found several CuV-seropositive individuals without viral DNA 
in the skin, with lower OD values. Notably, our study is the first to correlate CuV DNA and IgG 
occurrences within individuals and within patient cohorts. 
 
TuV DNA and IgG, on the other hand, have been strikingly rare or absent in any cohort. Only 
one child has been found TuV IgG reactive, and at low level [12], whereby the current 
transplant recipient is the second. TuV DNA has not been detected in any clinical material 
besides the Tunisian child [3]. Thus, more studies are needed to determine whether TuV really 
is a human virus.   
 
In conclusion, while BuV and TuV DNAs were not found in any tissue samples, CuV DNA was 
observed in both malignant and non-malignant skin of CTCL and immunosuppressed organ 
transplant patients but not in healthy skin of immunocompetent adults. Our study reveals a 
significantly higher CuV-DNA prevalence among the common subtypes of CTCL, compared 
with transplant recipients and healthy adults. This study further correlates the occurrences of 
CuV DNA and IgG in individual patients and cohorts. Our results thus suggest that human 
cutavirus is associated with CTCL. Whether this association can be generalized to all CTCL 
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subtypes and whether the role in carcinogenesis is causal, consequential, or casual must be 
determined in future prospective studies. 
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Tables and Figures 
 
 
 
Table 1. Protoparvovirus genoprevalence in CTCL, transplant, and healthy adult cohorts 
Patient 
cohort n CuV DNAa TuV DNA BuV DNA 
CTCL 25 4 (16.0%) 0 (0%) 0 (0%) 
Transplant 136 4 (2.9%) 0 (0%) 0 (0%) 
Healthy 
adults 98 0 (0%) 0 (0%) 0 (0%) 
aThe differences of CuV-DNA prevalence between CTCL and transplant recipients as well as CTCL and healthy 
adults were statistically highly significant (P < .0001) by Pearson's c2 test. 
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Table 2. CuV DNA-positive patients. Patient and sample information and CuV-DNA quantity 
in the sample. 
Cohort Patient Age, y/ gender Sampling site 
Sample 
taken 
Mean CuV 
DNA quantity 
per 1E+06 
cells 
Transplant/CTCL info;  
other diseases 
Transplant P-022 77 /  male 
Healthy skin 11.1.2013 4.51E+03a Liver transplanted 5.1.2003 
Serum 11.1.2013 Neg 
Transplant P-065 68 /  male 
Healthy skin 29.10.2013 3.92E+01a 
Liver transplanted 2.12.1991 
Diseased 2015 
Basal cell carcinoma 29.10.2013 3.35E+03a 
Serum 29.10.2013 Neg 
Transplant P-108 57 / female 
Healthy skin 16.12.2014 2.71E+03a 
Liver transplanted 2.10.2009 
Serum 30.1.2015 Neg 
Transplant P-A 81 /  male 
Healthy skin 
unknown  
2.54E+02 
Kidney transplanted 
26.8.1986  
and 25.6.1997 
Pre-malignant 
(carcinoma in situ) 2.28E+03
a 
Squamous cell 
carcinoma 1.00E+04
a 
CTCL C-81 57 /  male CTCL lesion 2016 1.07E+04
b 
CTCL/Sezary diagnosed 2016;  
Severe atopic eczema, 
erythroderma 
CTCL C-26 32 / male CTCL lesion 2016 5.83E+02
c CTCL/MF diagnosed 2016 
CTCL C-15 83 /  male CTCL lesion 2016 2.64E+01 
CTCL/MF diagnosed 2016;  
Prostate cancer 
 Additional 
samplesd 
Prostate A 2012 Neg 
 Prostate B 2015 Neg 
CTCL C-53 63 /  male CTCL lesion A 2015 3.35E+07
a 
CTCL/MF diagnosed 2015;  
Melanoma (no metastases),  
prostate cancer  
Additional 
samplesd 
 
 
Prostate, apex 2012 Neg 
 Prostate, basis 2012 Neg 
 
Lymph node 
(sentinel to 
prostate)  
2012 3.06E+03  
 Melanoma A 2013 7.18E+02  
 Melanoma B 2013 2.34E+02  
 Seborrheic keratosis 2013 6.91E+05  
 
Lymph node 
(sentinel to 
melanoma)  
2014 1.07E+05  
 Lymphocytic atypia 
(early CTCL) 2015 1.21E+08
a  
 Dysplastic nevus A  2015 5.54E+06a  
 Dysplastic nevus B 2015 4.84E+06a  
 CTCL lesion B  2015 7.26E+08a  
 Dermatofibroma 2015 1.65E+05  
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Neg, negative; MF, mycosis fungoides. 
aLonger 583-nt amplicons were sequenced of these tissues (Figure 1); bThis sample was also PCR positive with 
the primers CuV 230-fwd and CuV rev (Table S1); cThis 91-nt amplicon was 2-3 nt dissimilar to all other 
amplicons (Figure S2); dIn chronological order.  
 
 
 
Table 3. Protoparvovirus seroprevalence in transplant, CTCL and healthy adult cohorts 
Patient 
cohort 
n IgG towards 
any BuV 
BuV genotype-specific IgG TuV IgG CuV IgG 
BuV1 BuV2 BuV3 
CTCL  42 2 (4.8%) 2 (4.8%) 0 (0%) 0 (0%) 0 (0%) 4 (9.5%) 
Transplant 124 3 (2.4%) 1 (0.8%)a 1 (0.8%) 1 (0.8%) 1 (0.8%) 8 (6.5%)a 
Healthy 
adults 
78 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (3.8%) 
aone patient had both BuV1 and CuV IgG.  
The differences in seroprevalence did not reach statistical significance (Pearson’s c2 test). 
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Table 4. Longitudinal IgG EIA results (OD values) of BuV, TuV, or CuV IgG-positive transplant 
patients. All reactions showing OD>0.1 were confirmed with competition assay. 
Competition-confirmed IgG EIA results are marked with bold.  
Patient Transplant date 
Sampling 
date 
CuV DNA 
in skin 
Confirmed IgG 
EIA result BuV1 BuV2 BuV3 TuV CuV 
P-022 5.1.2003 5.1.2003  CuV 0.031 0.881 0.020 0.027 1.448 
  28.1.2003  CuV 0.016 0.254 0.015 0.011 0.554 
  11.1.2013 Pos CuV 0.008 1.262 0.008 0.007 2.165 
P-065 2.12.1991 1.12.1991  CuV 0.025 1.070 0.026 0.029 3.135 
  30.12.1991  CuV 0.008 0.204 0.017 0.016 0.805 
  29.10.2013 Pos CuV 0.023 0.435 0.024 0.021 1.477 
P-108 2.10.2009 30.6.2009  CuV 0.042 1.451 0.032 0.044 1.978 
  16.12.2014 Pos  serum not available 
  30.1.2015  CuV 0.019 0.579 0.019 0.026 1.241 
P-018 21.11.2003 21.11.2003  BuV1 and CuV 2.066 0.132 0.050 0.135 0.352 
  31.12.2012 Neg BuV1 and CuV 0.578 0.056 0.028 0.046 0.155 
P-012 14.11.2002 3.11.2002  CuV 0.025 0.140 0.022 0.025 0.415 
  1.12.2002  CuV 0.033 0.095 0.026 0.025 0.336 
  3.12.2012 Neg CuV 0.018 0.036 0.011 0.012 0.117 
P-037 7.3.2001 7.3.2001  CuV 0.038 0.420 0.042 0.090 1.256 
  27.3.2001  CuV 0.039 0.370 0.049 0.056 0. 830 
  13.3.2013 Neg CuV 0.062 0.282 0.055 0.121 0.829 
P-060 10.4.1994 27.11.2002  CuV 0.026 0.285 0.027 0.024 0.815 
  9.10.2013 Neg CuV 0.053 0.267 0.040 0.036 0.660 
P-093 1st tx 
19.3.1997, 
2nd tx: 
26.8.1998 
14.4.1997  Neg 0.022 0.027 0.015 0.017 0.028 
 25.8.1998  Neg 0.014 0.025 0.012 0.028 0.044 
 23.9.1998  Neg 0.019 0.026 0.022 0.019 0.030 
 12.3.2014 Neg CuV 0.034 0.143 0.023 0.021 0.294 
P-034 11.3.2007 20.12.2006  BuV2 0.064 0.169 0.037 0.044 0.067 
  21.4.2007  Neg 0.025 0.085 0.028 0.035 0.060 
  5.3.2013 Neg BuV2 0.038 0.168 0.022 0.025 0.033 
P-070 4.4.2002 23.2.2002  BuV3 0.015 0.018 0.333 0.016 0.024 
  17.5.2002  BuV3 0.014 0.014 0.120 0.015 0.023 
  12.11.2013 Neg BuV3 0.020 0.014 0.229 0.019 0.015 
P-055 12.8.2001 15.8.2001  CuV 0.042 0.053 0.045 0.057 0.232 
  28.2.2003  TuV 0.017 0.048 0.026 0.342 0.019 
  24.9.2013 Neg TuV 0.044 0.068 0.035 0.367 0.030 
Pos, positive; Neg, negative; tx, transplant. 
The difference in CuV OD values of corresponding serum samples from CuV DNA-positive and -negative 
recipients was statistically significant, P < .05 (Mann-Whitney U test). 
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Figure 1. Maximum likelihood phylogenetic tree made with 547-nt amplicons of CuV and 
BuV isolated from this study and worldwide. The tree was constructed with MEGA7, using 
the gamma distributed general time reverse model (GTR +G) with 1000 bootstrap resampling. 
The bootstrap values (≥ 70) are shown at nodes. Circles indicate isolates from this study. 
Name of each sequence indicates patient or virus strain number, the country of origin and 
sample type with existing GenBank accession numbers in the parentheses. Abbreviations: 
BHU, Bhutan; BOT, Botswana; BRA, Brazil; BUR, Burkina Faso; CHN, China; DEN, Denmark; FIN, 
Finland; FRA, France; TUN, Tunisia; TUR, Turkey. GenBank accession numbers of sequences in 
this study are MH822920-30. 
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